Last edition
News about "Intellectual Property (IP)"
ICMR Transfers 3 Indigenous Biomedical Technologies
ICMR has transferred 3 indigenous biomedical technologies, including an anti-HPV candidate and enteric vaccines, to accelerate cancer and infectious disease solutions.
Intellectual Property (IP) | 23/07/2026 | By News Bureau
India and Australia Sign CSIR-TKDL Pact to Protect Traditional Knowledge
CSIR and IP Australia have signed a Traditional Knowledge Digital Library (TKDL) access agreement at the India-Australia Summit to strengthen traditional knowledge protection.
Intellectual Property (IP) | 13/07/2026 | By News Bureau
Syngene Partners with Johns Hopkins University for Early Drug Discovery
The collaboration between Syngene International and John Hopkins University is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research.
Intellectual Property (IP) | 13/02/2026 | By News Bureau | 190
USPTO Issues New Patent to Acurx for DNA Polymerase IIIC Inhibitor Technology
The newly granted patent covers DNA polymerase IIIC inhibitors, including compositions of matter, methods of use and pharmaceutical formulations, further strengthening Acurx’s Intellectual Property (IP) portfolio and expanding its growing patent estate in the US and international markets.
Intellectual Property (IP) | 03/02/2026 | By News Bureau | 164
Atossa Therapeutics Receives FDA Go-Ahead for (Z)-Endoxifen IND in Metastatic Breast Cancer
Atossa Therapeutics announced that it has received a “Study May Proceed” letter from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for (Z)-endoxifen in metastatic breast cancer, clearing the way for the initiation of clinical studies evaluating the therapy.
Intellectual Property (IP) | 07/01/2026 | By News Bureau | 306
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy